Establishing a national cohort for juvenile recurrent respiratory papillomatosis in France

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish the epidemiology of juvenile recurrent respiratory papillomatosis (RRP), the most common benign laryngeal tumor in children, in France. It will collect data from reference centers to better understand the disease's epidemiology, risk factors, genetic susceptibility, and clinical manifestations. The study will also evaluate the efficacy of existing therapies and preventive measures to create standardized treatment guidelines. By gathering this data, the study seeks to fill the gap in the current lack of epidemiological information on RRP in France.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with juvenile PRR (disease onset before age 18)
* Followed in the :

  * The MALO CRMR
  * One of the MALO network's CCMRs
  * One of the main correspondent centers

Exclusion Criteria:

* Patients objecting to the collection of their personal data
* Parents of minor patients objecting to the collection of their child's personal data

Where it's running

• hôpital Necker Enfants malades
  Paris, France Recruiting

Study contacts

• Study coordinator: Nicolas LEBOULANGER, MD
• Email: nicolas.leboulanger@aphp.fr
• Phone: 0144494682

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Autologous dendritic cell vaccine for recurrent respiratory papillomatosis

  This test tries a vaccine made from your own dendritic cells loaded with HPV6 peptides to see if it is safe and stimulates the immune system in people with HPV6-positive recurrent respiratory papillomatosis.

  Recruiting Phase 1 Mayo Clinic · Scottsdale, Arizona · NCT07317154

• Treatment of Recurrent Respiratory Papillomatosis with PRGN-2012

  This study is testing a new treatment called PRGN-2012 in adults with recurrent respiratory papillomatosis to see if it helps reduce their symptoms after multiple surgeries.

  Recruiting at 3 sites Phase 4 Precigen, Inc · Atlanta, Georgia and 2 other locations · NCT06538480

• Understanding the biology of Pulmonary Recurrent Respiratory Papillomatosis

  This study is collecting tissue samples from patients with Pulmonary Recurrent Respiratory Papillomatosis to better understand the disease and find new treatments.

  Recruiting Massachusetts General Hospital · New Haven, Connecticut · NCT06412172

• Pembrolizumab plus lenvatinib for HPV-related recurrent respiratory papillomatosis with lung involvement

  This research will try pembrolizumab together with lenvatinib in adults who have HPV-associated recurrent respiratory papillomatosis that involves the lungs.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT04645602

• Registry for patients with rare diseases

  This study is creating a central registry for people with rare diseases to help connect them with researchers and improve treatments.

  Recruiting Sanford Health · Sioux Falls, South Dakota · NCT01793168

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.